CN107496573A - Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease - Google Patents
Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease Download PDFInfo
- Publication number
- CN107496573A CN107496573A CN201710718112.4A CN201710718112A CN107496573A CN 107496573 A CN107496573 A CN 107496573A CN 201710718112 A CN201710718112 A CN 201710718112A CN 107496573 A CN107496573 A CN 107496573A
- Authority
- CN
- China
- Prior art keywords
- herba houttuyniae
- volatile oil
- reperfusion injury
- houttuynia
- myocardial ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 36
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 35
- 235000013717 Houttuynia Nutrition 0.000 title claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 18
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 6
- 240000000691 Houttuynia cordata Species 0.000 title abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000007654 immersion Methods 0.000 claims abstract description 7
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 7
- 239000007901 soft capsule Substances 0.000 claims abstract description 4
- 235000013376 functional food Nutrition 0.000 claims abstract description 3
- 239000000341 volatile oil Substances 0.000 claims description 73
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 72
- 230000000694 effects Effects 0.000 claims description 29
- 241000758769 Houttuynia Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 241000700159 Rattus Species 0.000 abstract description 44
- 238000011282 treatment Methods 0.000 abstract description 7
- 210000004165 myocardium Anatomy 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 25
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 18
- 229960003957 dexamethasone Drugs 0.000 description 18
- 102000004889 Interleukin-6 Human genes 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 229940100601 interleukin-6 Drugs 0.000 description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 description 13
- 108010012715 Superoxide dismutase Proteins 0.000 description 13
- 206010061216 Infarction Diseases 0.000 description 12
- 230000007574 infarction Effects 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 206010003119 arrhythmia Diseases 0.000 description 8
- 230000006793 arrhythmia Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 206010047302 ventricular tachycardia Diseases 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HEVGGTGPGPKZHF-UHFFFAOYSA-N 1-(1,2-dimethyl-3-methylidenecyclopentyl)-4-methylbenzene Chemical compound CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920002334 Spandex Polymers 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960005143 amobarbital sodium Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- BNHGKKNINBGEQL-UHFFFAOYSA-M sodium;5-ethyl-5-(3-methylbutyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CC(C)CCC1(CC)C(=O)NC(=O)[N-]C1=O BNHGKKNINBGEQL-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- XJLDYKIEURAVBW-UHFFFAOYSA-N 3-decanone Chemical compound CCCCCCCC(=O)CC XJLDYKIEURAVBW-UHFFFAOYSA-N 0.000 description 1
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to biomedicine field, and in particular to application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease.Cordate houttuynia is Saururaceae heartleaf houttuynia platymiscium heartleaf houttuynia Houttuynia cordata Thunb. herb, pass through frost, crush, immersion, filtering, the techniques such as concentration are made soft capsule or the preparation for being available for clinical practice are made according to pharmacy technique, the houttuynia extract preparation can be obviously improved the myocardial infarction area of myocardial ischemia-reperfusion injury in rats, prompt houttuynia extract preparation that there is obvious preventive and therapeutic action to myocardial ischemia-reperfusion injury relevant disease, human myocardium's ischemical reperfusion injury relevant disease prevention and treatment medicine or functional food can be used as.
Description
Technical field
The present invention relates to biomedicine field, and in particular to houttuynia extract is preparing preventing and treating myocardial ischemia-reperfusion damage
Hinder the application in the pharmaceutical preparation of relevant disease.
Background technology
Myocardial ischemia disease, also known as coronary heart disease, it is one of common multiple disease of cardiovascular system, the whole world there are about every year
23500000 people die from coronary heart disease, and the fatal rate of its myocardial infarction accounts for second.Myocardial infarction is due primarily to coronary blood
For reducing or interrupting, cause cardiac muscle cell's hypoxic-ischemic, finally cause a kind of disease of myocardium cell necrosis.Clinically lead at present
It is the blood flow by recovering ischemic myocardium as early as possible to want therapy approach, increases CBF, improves microcirculation etc. to save the dying heart
Myocyte, therefore, fast quick-recovery Reperfu- sion are the unique effective ways for treating acute myocardial infarction AMI.
Clinically there is the methods of PCI, operative treatment, drug therapy, gene therapy.Although the certain journey of above method
The anoxic conditions of cardiac muscle cell are alleviated on degree, but it is bad to be subsequently found its clinical effectiveness.But numerous studies find the ischemic heart
Flesh Reperfu- sion can also induce a series of new pathophysiological changes in itself, further aggravate the damage of cardiac bistiocyte, occur
Reperfu- sion arrhythmia cordis, myocardial systolic property obstacle, metabolic disorder and myocardial ultrastructure change etc., i.e. myocardial ischemia-reperfusion
Damage (Myocardialischemia-reperfusion injury, MIRI).Research shows that inflammation and redox damage exist
Played an important role in myocardial ischemia-reperfusion injury occurrence and development.At present clinically using Antioxidation Treatment, calcium antagonist, statin
The exploration treatment MIRI such as class, but clinical efficacy is bad.It is external at present to use the medicines such as Abciximab, ciclosporin A, Exenatide
Thing enters the second stage of clinical treatment MIRI, though there is certain curative effect, effect is limited.Therefore find and safely and effectively prevent and treat myocardial ischemia again
Perfusion injury new drug is the most important thing of current research work.
Cordate houttuynia is Saururaceae heartleaf houttuynia platymiscium heartleaf houttuynia Houttuynia cordata Thunb. herb, mainly into
It is divided into volatile oil, mainly including decanoyl acetaldehyde, methylnonanone, Bronyl acetate, firpene, phellandrene, laurene, limonene
Deng pharmacological action is extensive, has anti-inflammatory, anti-oxidant, antibacterial, antiviral, antitumor, the increase multiple efficacies such as immunity, prompts
Herba Houttuyniae volatile oil has protective effect to myocardial ischemia-reperfusion injury.Studies have found that Herba Houttuyniae volatile oil can reduce
IL-8 and MDA content in rat chronic model of lung injury lung tissue caused by LPS.The houttuynia cordata injection of listing has been developed to imitate
The features such as fruit is obvious, cheap, and adverse reaction is few has been widely used in clinic, be mainly used in treating breathing, digestion, gynaecology,
The diseases such as andrology, uropoiesis, ear nose larynx, ophthalmology, oral cavity, skin, and the research such as Guo Yali finds that gavage gives Herba Houttuyniae volatile oil
100mg/kg does not have found that toxic reaction or death occurs in rat, shows that Herba Houttuyniae volatile oil oral toxicity is relatively low, mouth is such as made
Formulation has preferable DEVELOPMENT PROSPECT.
There is not been reported for research of the Herba Houttuyniae volatile oil to myocardial ischemia-reperfusion injury at present, and this problem has in searching
It is obvious to find that Herba Houttuyniae volatile oil has to myocardial ischemia-reperfusion injury in the research of the reperfusion injury that resists myocardial ischemia effect
Protective effect, can as clinical prevention and treatment myocardial ischemia-reperfusion relevant disease medicine.
The content of the invention
Problem to be solved by this invention is to provide a kind of Chinese medical extract for the reperfusion injury that resists myocardial ischemia, to subtract
Less or avoid myocardial ischemia-reperfusion injury.
To reach above-mentioned purpose, the present invention provides following technical scheme：
Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease.
Further, the myocardial ischemia-reperfusion injury relevant disease, refers to myocardial infarction or coronary heart disease.
Further, the houttuynia extract is the Herba Houttuyniae volatile oil for extracting to obtain from cordate houttuynia.
Further, the extracting method of the Herba Houttuyniae volatile oil is using cordate houttuynia as raw material, with steam distillation, is surpassed
Supercritical fluid extraction method and organic solvent extraction extract to obtain Herba Houttuyniae volatile oil.
Further, the extracting method of the Herba Houttuyniae volatile oil, is comprised the following steps that：
S1. fresh cordate houttuynia is taken under the conditions of -50 DEG C~-80 DEG C, is freezed 6~12 hours；
S2. colod-application Baily pulverizer is taken advantage of to carry out being ground into fine powder；
S3. and then by fine powder and -4 DEG C~-8 DEG C distilled water solid-liquid ratio 1 is pressed：5~10 immersions 12~24 hours；
S4. in Rotary Evaporators 50 DEG C~70 DEG C flow back 4~8 hours；
S5. the preparation for being available for Clinical practice is finally made by pharmacy technique.
Further, the extracting method of the Herba Houttuyniae volatile oil is to take fresh -80 DEG C of cordate houttuynia to freeze 9 hours, is taken advantage of cold
Carried out being ground into fine powder with Baily pulverizer, 6 DEG C of distilled water press solid-liquid ratio 1：7.5 immersions 18 hours, in Rotary Evaporators
60 DEG C are flowed back 6 hours, and gained Herba Houttuyniae volatile oil yield is maximum, and the reperfusion injury curative effect that resists myocardial ischemia is optimal.
Further, the preparation is the soft capsule of houttuynia extract preparation, pill, oral liquid, spray.
The present invention confirms that Herba Houttuyniae volatile oil can significantly reduce myocardial ischemia-reperfusion injury by animal pharmacological experiment
Myocardial infarction area, effectively mitigate myocardial ischemia-reperfusion injury, therefore the Chinese medical extract can be applied to prevent or treat the heart
Myocardial ischemia reperfusion injury relevant disease, such as coronary heart disease, myocardial infarction, there is huge clinical value.
The Herba Houttuyniae volatile oil that the present invention mentions can be prepared into soft capsule, pill, oral liquid, spray, for facing
Bed is as prevention or the application for the pharmaceutical preparations for treating myocardial ischemia-reperfusion injury relevant disease, or in functional food
Using.
Brief description of the drawings
Fig. 1 is that (NBT is dyed, and white portion is stalk for influence of the Herba Houttuyniae volatile oil to rat MIRI phantom heart infarct rates
Dead band).
Wherein, A is sham-operation group, and B is model group, and C is dexamethasone positive controls (DEX groups, 0.8mg.kg-1.d-1), D is Herba Houttuyniae volatile oil low dose group (YXC-L groups, 5mg.kg-1.d-1), E is Herba Houttuyniae volatile oil middle dose group (XYC-M
Group, 10mg.kg-1.d-1), F is Herba Houttuyniae volatile oil high dose group (XYC-H groups, 20mg.kg-1.d-1)。
Embodiment
With reference to specific embodiment, the present invention is expanded on further.It should be understood that following examples are merely to illustrate the present invention
Rather than limitation the scope of the present invention, every equivalent substitution according to made by the disclosure of invention, belong to the present invention
Protection domain.
Protective effect and Mechanism Study of the Herba Houttuyniae volatile oil of embodiment 1 to myocardial ischemia-reperfusion injury
1. material
1.1 instrument
DGG-9070B electric drying oven with forced convections (Shanghai gloomy reliable test Instrument Ltd.)；HC-280T2 Universalpulverizers
(Yongkang City green can Food Machinery Co., Ltd.)；Rotary Evaporators (Shanghai Yarong Biochemical Instrument Plant)；BL-420F biological functions are real
Check system (Chengdu TME Technology Co., Ltd.)；RM2255 Lycras slicer (German Lycra instrument company)；HX-101E animals exhale
Suction machine (Shanghai Alcott bio tech ltd)
1.2 medicines and reagent
Dexamethasone tablet：Specification 0.75mg/ pieces, GuangDong HuaNan Pharmacy Group Co., Ltd；Cordate houttuynia：Guangdong day Thailand medicine company
Co., Ltd；Creatine kinase (CK), lactic dehydrogenase (LDH), superoxide dismutase (SOD), MDA (MDA) detection reagent
Box：Limited company is built up in Nanjing；Tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) ELISA detection kit：It is rich
Shi De Bioisystech Co., Ltd；NBT (NBT)：Sigma-Aldrich
1.3 animal
SPF level SD rats 60, male and female half and half, body weight 180-220g, are provided by Shandong Province's Experimental Animal Center, and animal is closed
Lattice card number：SCXK (Shandong) 20140006.
2. method
The extraction of 2.1 Herba Houttuyniae volatile oils
Selection freezing temperature, frost time, solvent temperature, solid-liquid ratio, soak time, evaporation time and return time, seven
Individual each three levels of factor do Orthogonal Experiment and Design, screen optimum extraction process.Specific method is as follows：Fresh cordate houttuynia is taken, point
Not under the conditions of -50 DEG C, -65 DEG C, -80 DEG C, 6h, 9h, 12h are freezed, colod-application Baily pulverizer is taken advantage of and carries out being ground into fine powder；So
Fine powder and -4 DEG C, 6 DEG C, 8 DEG C of distilled water are pressed into solid-liquid ratio 1 afterwards：5、1：7.5、1：10 immersion 12h, 18h, 24h, steam in rotation
50 DEG C, 60 DEG C, 70 DEG C of backflows 4h, 6h, 8h are sent out in instrument, calculate yield, yield (%)=volatilization weight of oil (g)/medicinal material weight
(g)*100
2.2 packets and administration
Animal adaptability by body weight is randomly divided into sham-operation group, model group, dexamethasone positive controls after feeding 1 week
(DEX groups), Herba Houttuyniae volatile oil low dose group (YXC-L groups), Herba Houttuyniae volatile oil middle dose group (YXC-M groups), cordate houttuynia is waved
Hair oil high dose group (YXC-H groups), every group 10.Continuous gavage is administered 2 weeks before modeling, dexamethasone positive controls gavage
0.8mg.kg is administered-1.d-1, the basic, normal, high dosage group difference gastric infusion 5mg.kg of Herba Houttuyniae volatile oil-1.d-1, 10mg.kg- 1.d-1, 20mg.kg-1.d-1, sham-operation group, model group gavage give normal saline.
The foundation of 2.3 rat MIRI models
After each group rat continuous gavage is administered 2 weeks, start modeling after last dose 0.5h, with 4% amobarbital sodium fiber crops
Liquor-saturated rat, lie on the back and be fixed on 37 DEG C of constant operation tables after anesthesia, direct oral cavity trachea cannula, connection lung ventilator (frequency be 75~
85 times/min, tidal volume 1.5mL/100g, exhale, inhale than being 3: 2), maintain breathing.Four limbs connect conducting wire, connect biological function
Experimental system, record II lead electrocardiogram.Chest hair, iodophor disinfection are shaved off, cuts left side the 3rd, 4 breastbones, device of removing the fine hairs on the face and neck and tidy up hairline at temples struts
Chest, exposure heart, tears pericardium, ligatures the coronary artery left anterior descending branch between atrium sinistrum and pulmonary conus, sham-operation
Group, which only threads, not to ligature.Extrusion chest intracavity gas simultaneously close thoracic cavity, with left room antetheca become bletilla electrocardiogram show ST sections raise into
Ligature Success Flag.Chest is opened after ligation ischemic 30min and cuts ligature, Reperfu- sion 24h, establishes rat MIRI models.
2.4 arrhythmia cordis are evaluated
The lead electrocardiogram of rat body surface II is monitored, records Ventricular Tachycardia, VPB and room after Reperfu- sion 30min
Quiver situation.Commented with reference to Ravingerova T etc. method progress ventricular arrhythmia (Ventricular arrhythmia, VA)
Point, standards of grading are shown in Table 1.
The arrhythmia cordis standards of grading of table 1
| VA scores | VA types |
| 0 | Without VA or have, but ＜ 5 times VPB |
| 1 | Only ＞ 5 times VPB |
| 2 | Only a burst of ＜ 60s Ventricular Tachycardia |
| 3 | There are a burst of ＞ 60s's or more gusts of accumulative ＜ 60s' Ventricular Tachycardias |
| 4 | More gusts of accumulation ＞ 60s Ventricular Tachycardia |
| 5 | Quiver room |
| 6 | Lasting >=5min room is quivered or death |
2.5 materials
After Reperfu- sion 24h, 4% amobarbital sodium anesthetized rat, arteria carotis communis takes blood 2ml, is placed in EDTA-2K anticoagulant tubes
In, 3000r/min centrifugation 15min, separated plasma, -20 DEG C preserve, to be measured.Thoracic cavity is splitted, wins heart, is rushed with physiological saline
Wash clean, -20 DEG C of refrigerators freeze 30min, 2mm cardiac muscular tissues are cut under ligature, in 37 DEG C of incubators, 0.05%NBT dye liquors
Middle dyeing 20min, scanning.Rat heart infarct rate, infarct rate are calculated using Image-Pro Plus image analysis processing softwares
=infarct size/the gross area × 100%.
2.6 biochemical indicators detect
Using enzyme kinetics method detection Plasma CK, LDH activity；TNF- in blood plasma is detected using ELISA double antibody sandwich methods
α, IL-6 content；WST-1 methods detection SOD activity, TBA methods detection MDA contents.Experimental implementation is entered according to kit specification
OK.
2.7 statistical method
Statistical analysis is carried out using the softwares of SPSS 17.0.Measurement data is represented with x ± s.Data carry out homogeneity of variance and
Test of normality, if not meeting person, using one-way analysis of variance；If not meeting normal distribution or heterogeneity of variance person, use
Non-parametric rank sum test.Inspection level α=0.05, P ＜ 0.05 is that difference is statistically significant.
2. result
The influence that 2.1 various extracting conditions extract to Herba Houttuyniae volatile oil
The influence that the various extracting conditions of table 2 extract to Herba Houttuyniae volatile oil
From the result of table 2：Take -80 DEG C of fresh cordate houttuynia to freeze 9 hours, take advantage of colod-application Baily pulverizer be ground into it is micro-
Fine powder, 6 DEG C of distilled water press solid-liquid ratio 1：7.5 immersions 18 hours, 60 DEG C are flowed back 6 hours in Rotary Evaporators, gained cordate houttuynia
The oil yield that volatilizees is maximum.
Influence of 2.1 Herba Houttuyniae volatile oils to rat MIRI model arrhythmia cordis
The not normal appraisal result of each group rat heart rate of table 3
| Group | Each group rat ventricular appraisal result | Mean rank order |
| Sham-operation group | 0 0 0 0 0 0 0 0 0 0 | 6.50 |
| Model group | 4 3 6 5 5 4 5 4 6 5 | 50.20 |
| DEX groups | 3 4 3 2 2 3 2 3 2 2 | 25.00 |
| YXC-L groups | 3 4 4 5 5 6 5 5 44 | 47.30 |
| YXC-M groups | 2 3 2 3 4 5 3 3 4 3 | 35.70 |
| YXC-H groups | 2 3 2 2 3 2 3 2 2 3 | 18.3 |
Note：X2=49.746, P ＜ 0.05
From the result of table 3：Compared with sham-operation group, model group rats arrhythmia cordis more early occurs and the duration compared with
Long, generation is quivered frequently in VPB, Ventricular Tachycardia and room, shows that model group rats arrhythmia cordis is more serious.With model group
Compare, Herba Houttuyniae volatile oil low dose group rat ventricular is also more serious；The middle and high dosage group of Herba Houttuyniae volatile oil and ground plug rice
Pine group rat ventricular degree significantly mitigates, and is in dose dependent.
Influence of 2.2 Herba Houttuyniae volatile oils to rat MIRI phantom heart infarct rates
The each group rat heart infarct rate of table 4 changes
| Group | Quantity (only) | Infarct rate |
| Sham-operation group | 10 | 0 |
| Model group | 10 | 51.25±5.36** |
| DEX groups | 10 | 32.68±4.86**# |
| YXC-L groups | 10 | 35.89±6.41*# |
| YXC-M groups | 10 | 19.64±3.57**## |
| YXC-H groups | 10 | 13.74±2.26**##^& |
Note：Compared with sham-operation group, * p<0.05,**p<0.01, compared with model group,#p<0.05,##p<0.01, with DEX
Group compares, ^p<0.05,^^p<0.01, the , ＆p compared with YXC-L groups<0.05,&&p<0.01
From table 4 and Fig. 1 results：Compared with sham-operation group, the significantly raised (P of each group rat heart infarct rate<
0.05).Compared with model group, the basic, normal, high dosage group rat heart infarct rate of Dexamethasone group, Herba Houttuyniae volatile oil is notable
Reduce (P<0.05).Compared with Dexamethasone group, Herba Houttuyniae volatile oil high dose group rat heart infarct rate significantly reduces (P<
0.05).Compared with Herba Houttuyniae volatile oil low dose group, Herba Houttuyniae volatile oil high dose group rat heart infarct rate significantly reduces (P
<0.05)。
Influence of 2.3 Herba Houttuyniae volatile oils to rat MIRI models Plasma CK, LDH activity
The each group rat plasma CK of table 5 and LDH activity change
| Group | Quantity (only) | CK | LDH |
| Sham-operation group | 10 | 212±25.67 | 2580.82±279.04 |
| Model group | 10 | 522.20±47.01** | 3508.28±341.52** |
| DEX groups | 10 | 383.875±49.91**# | 3099.24±301.01**# |
| YXC-L groups | 10 | 452.54±50.86**# | 3104.26±412.13**# |
| YXC-M groups | 10 | 317.36±34.86**## | 2932.58±212.13**## |
| YXC-H groups | 10 | 255.34±35.8##^^&& | 2784.93±216.79##^^& |
Note：Compared with sham-operation group,*p<0.05,**p<0.01, compared with model group,#p<0.05,##p<0.01, with DEX
Group compares,^p<0.05,^^p<0.01, compared with YXC-L groups,&p<0.05,&&p<0.01
From the result of table 5：Compared with sham-operation group, model group, dexamethasone positive controls, Herba Houttuyniae volatile oil
Low, middle dose group (P<0.01).Compared with model group, the basic, normal, high dosage group rat serum of Dexamethasone group, Herba Houttuyniae volatile oil
Slurry CK and LDH activity significantly reduce (P<0.05).Compared with Dexamethasone group, Herba Houttuyniae volatile oil high dose group rat plasma
CK and LDH activity significantly reduce (P<0.01).Compared with Herba Houttuyniae volatile oil low dose group, Herba Houttuyniae volatile oil high dose group
Rat plasma CK and LDH activity significantly reduce (P<0.05).
Influence of 2.4 Herba Houttuyniae volatile oils to rat MIRI model Plasma TNFs-α, IL-6
The each group rat plasma TNF-α of table 6 and IL-6 changes of contents
| Group | Quantity (only) | TNF-α | IL-6 |
| Sham-operation group | 10 | 37.02±2.36 | 75.88±2.79 |
| Model group | 10 | 192.29±2.701** | 308.28±3.45** |
| DEX groups | 10 | 103.85±4.99**# | 178.29±3.01**# |
| YXC-L groups | 10 | 125.46±5.86**# | 194.23±8.11**## |
| YXC-M groups | 10 | 92.36±3.84**## | 142.87±5.51**# |
| YXC-H groups | 10 | 55.32±3.58##^^&& | 94.99±6.17##^^&& |
Note：Compared with sham-operation group,*p<0.05,**p<0.01, compared with model group,#p<0.05,##p<0.01, with DEX
Group compares,^p<0.05,^^p<0.01, compared with YXC-L groups,&p<0.05,&&p<0.01
From the result of table 6：Compared with sham-operation group, model group, dexamethasone positive controls, Herba Houttuyniae volatile oil
Low, middle dose group rat plasma TNF-α and the significantly raised (P of IL-6 contents<0.01).Compared with model group, dexamethasone sun
Property control group, the basic, normal, high dosage group rat plasma TNF-α of Herba Houttuyniae volatile oil and IL-6 contents significantly reduce (P<0.05).
Compared with dexamethasone positive controls, Herba Houttuyniae volatile oil high dose group rat plasma TNF-α and IL-6 contents significantly drop
Low (P<0.01).Compared with Herba Houttuyniae volatile oil low dose group, Herba Houttuyniae volatile oil high dose group rat plasma TNF-α and IL-6
Content significantly reduces (P<0.01).
Influence of 2.5 Herba Houttuyniae volatile oils to rat MIRI models plasma SOD, MDA
The each group rat plasma SOD of table 7 activity and MDA changes of contents
Note：Compared with sham-operation group,*p<0.05,**p<0.01, compared with model group,#p<0.05,##p<0.01, with DEX
Group compares,^p<0.05,^^p<0.01, compared with YXC-L groups,&p<0.05,&&p<0.01
From the result of table 7：Compared with sham-operation group, model group, dexamethasone positive controls, Herba Houttuyniae volatile oil
Low, middle dose group rat plasma SOD activity significantly reduces (P<0.01), MDA contents significantly raise (P<0.01).With model group ratio
Compared with the basic, normal, high dosage group rat plasma SOD activity of dexamethasone positive controls, Herba Houttuyniae volatile oil significantly rise (P<
0.05), MDA contents significantly reduce (P<0.05).Compared with dexamethasone positive controls, Herba Houttuyniae volatile oil high dose group is big
Mouse activity of plasma SOD significantly raises (P<0.01), MDA contents significantly reduce (P<0.01).With Herba Houttuyniae volatile oil low dose group
Compare, Herba Houttuyniae volatile oil high dose group rat plasma SOD activity significantly rise (P<0.01), MDA contents significantly reduce (P<
0.01)。
3. discuss
3.1 Herba Houttuyniae volatile oils are obviously improved parameters of left ventricular function and myocardial cell injury
The arrhythmia cordis order of severity and CK, LDH activity level are all the weights for evaluating heart function and myocardium cell injuring degree
Index is wanted, the study find that model group rats degree of arrhythmia is serious, significantly raises CK, LDH activity.Research shows model group
Myocardial ischemia-reperfusion injury is serious, prompts modeling success.And the middle and high dosage group of Herba Houttuyniae volatile oil substantially mitigates arrhythmia cordis
Degree, Plasma CK, LDH activity are significantly reduced, in dose dependent, show that the middle and high dosage group of Herba Houttuyniae volatile oil can be protected effectively
The integrality of shield heart muscle cell membrane, spilling for CK and LDH is reduced, so as to mitigate myocardial ischemia-reperfusion injury, and cordate houttuynia is waved
Hair oil high dose group effect is best.Dexamethasone positive controls can also mitigate myocardial ischemia-reperfusion injury, but effect is too late
Herba Houttuyniae volatile oil high dose group, and each group rat heart infarct rate is consistent with These parameters result.
3.2 Herba Houttuyniae volatile oils are obviously improved inflammation index
TNF-α has the cellular inflammation factor of a variety of biological effects with IL-6, participates in Various Tissues reperfusion injury, both
Content height can reflect severity of inflammation, especially closely related with inflammation caused by neutrophil leucocyte.The study find that model group
Rat TNF-α, IL-6 contents significantly raise, and give the basic, normal, high dosage of Herba Houttuyniae volatile oil can significantly reduce Plasma TNF-α,
IL-6, and be in dose dependent, show that the basic, normal, high dosage group of Herba Houttuyniae volatile oil can substantially reduce inflammation, and cordate houttuynia is volatilized
Oily high dose group effect is best.Dexamethasone positive controls can also reduce Plasma TNF-α, IL-6, but effect is not as good as cordate houttuynia
Volatile oil high dose group.
3.3 Herba Houttuyniae volatile oils are obviously improved Antioxidant Indexes
SOD and MDA is the important indicator of the degree of injury of the Scavenging activity and oxidative stress that reflect body free radical.Originally grind
Study carefully and find that model group rats activity of plasma SOD significantly raises, MDA contents significantly reduce, and it is basic, normal, high to give Herba Houttuyniae volatile oil
Dosage can significantly raise activity of plasma SOD, reduce MDA contents, and be in dose dependent, show that Herba Houttuyniae volatile oil is basic, normal, high
Dosage group can substantially mitigate oxidativestress damage, and the wherein basic, normal, high dosage group effect of Herba Houttuyniae volatile oil is more preferable.Dexamethasone
Positive controls can also raise activity of plasma SOD, reduce MDA contents, but effect is not as good as Herba Houttuyniae volatile oil high dose group.
4. conclusion
Herba Houttuyniae volatile oil has preferable protective effect to myocardial ischemia-reperfusion injury, and wherein gavage is given
20mg.kg-1.d-1Effect is best, and its mechanism of action may be by reducing inflammation relevant with anti-peroxidation damage, and it can conduct
Medicinal application is in prevention or treatment myocardial ischemia-reperfusion injury relevant disease.
Claims (8)
1. application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease.
2. houttuynia extract according to claim 1 is preparing the medicine of preventing and treating myocardial ischemia-reperfusion injury relevant disease
Application in thing preparation, it is characterised in that the myocardial ischemia-reperfusion injury relevant disease, refer to myocardial infarction or coronary disease
Disease.
3. houttuynia extract according to claim 1 is preparing the medicine of preventing and treating myocardial ischemia-reperfusion injury relevant disease
Application in thing preparation, it is characterised in that the houttuynia extract is the Herba Houttuyniae volatile oil for extracting to obtain from cordate houttuynia.
4. the extracting method of the Herba Houttuyniae volatile oil described in claim 3, it is characterised in that using cordate houttuynia as raw material, steamed with water
Steam distillation method, supercritical fluid extraction and organic solvent extraction extract to obtain Herba Houttuyniae volatile oil.
5. the extracting method of Herba Houttuyniae volatile oil according to claim 4, it is characterised in that comprise the following steps that：
S1. fresh cordate houttuynia is taken under the conditions of -50 DEG C ~ -80 DEG C, is freezed 6 ~ 12 hours；
S2. colod-application Baily pulverizer is taken advantage of to carry out being ground into fine powder；
S3. and then by fine powder and -4 DEG C ~ -8 DEG C distilled water solid-liquid ratio 1 is pressed：5 ~ 10 immersions 12 ~ 24 hours；
S4. in Rotary Evaporators 50 DEG C ~ 70 DEG C flow back 4 ~ 8 hours；
S5. the preparation for being available for Clinical practice is finally made by pharmacy technique.
6. the extracting method of Herba Houttuyniae volatile oil according to claim 5, it is characterised in that take fresh -80 DEG C of cordate houttuynia
Frost 9 hours, takes advantage of colod-application Baily pulverizer and carries out being ground into fine powder, 6 DEG C of distilled water press solid-liquid ratio 1：7.5 immersion 18 hours,
60 DEG C are flowed back 6 hours in Rotary Evaporators, and gained Herba Houttuyniae volatile oil yield is maximum, and resist myocardial ischemia reperfusion injury curative effect
Most preferably.
7. the extracting method of Herba Houttuyniae volatile oil according to claim 5, it is characterised in that the preparation is waved for cordate houttuynia
The soft capsule of hair oil preparation, pill, oral liquid, spray.
8. application of the Herba Houttuyniae volatile oil described in claim 3 in functional food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710718112.4A CN107496573B (en) | 2017-08-21 | 2017-08-21 | Application of houttuynia cordata extract in preparation of pharmaceutical preparation for preventing myocardial ischemia reperfusion injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710718112.4A CN107496573B (en) | 2017-08-21 | 2017-08-21 | Application of houttuynia cordata extract in preparation of pharmaceutical preparation for preventing myocardial ischemia reperfusion injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107496573A true CN107496573A (en) | 2017-12-22 |
| CN107496573B CN107496573B (en) | 2021-02-02 |
Family
ID=60691459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710718112.4A Active CN107496573B (en) | 2017-08-21 | 2017-08-21 | Application of houttuynia cordata extract in preparation of pharmaceutical preparation for preventing myocardial ischemia reperfusion injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496573B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107961288A (en) * | 2017-12-14 | 2018-04-27 | 西安交通大学 | Application of the cordate houttuynia water extract in the medicine for improving aortic endothelial cell function is prepared |
| CN112869154A (en) * | 2021-01-13 | 2021-06-01 | 南昌大学 | Herba houttuyniae volatile oil heart-protecting capsule for toxicity attenuation and efficacy enhancement in chemotherapy and preparation method thereof |
| CN114983937A (en) * | 2022-01-19 | 2022-09-02 | 中国医学科学院药物研究所 | Houttuynia cordata volatile oil self-microemulsion and preparation method and application thereof |
-
2017
- 2017-08-21 CN CN201710718112.4A patent/CN107496573B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107961288A (en) * | 2017-12-14 | 2018-04-27 | 西安交通大学 | Application of the cordate houttuynia water extract in the medicine for improving aortic endothelial cell function is prepared |
| CN112869154A (en) * | 2021-01-13 | 2021-06-01 | 南昌大学 | Herba houttuyniae volatile oil heart-protecting capsule for toxicity attenuation and efficacy enhancement in chemotherapy and preparation method thereof |
| CN114983937A (en) * | 2022-01-19 | 2022-09-02 | 中国医学科学院药物研究所 | Houttuynia cordata volatile oil self-microemulsion and preparation method and application thereof |
| CN114983937B (en) * | 2022-01-19 | 2023-11-07 | 中国医学科学院药物研究所 | Houttuynia cordata volatile oil self-microemulsion and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107496573B (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107496573A (en) | Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease | |
| CN107007689A (en) | A kind of Chinese medicine preparation of temperature compensation heart kidney and its production and use | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| CN103070943A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN106728734B (en) | A kind of cold medicine for treatment flu | |
| CN102716230A (en) | Novel applications of cape jasmine extract product in preparation of drugs | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN110292607A (en) | The Chinese medicine composition and preparation method for treating the concurrent left ventricular hypertrophy of high blood pressure | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN104857393A (en) | Pharmaceutical preparation for treating arrhythmia | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN101167767B (en) | Hypericum attenuatum extraction and its application for preparing medicine for treating cardiac diseases | |
| CN104189288B (en) | A kind of Chinese medicine composition for treating myocardial infarction and its application | |
| CN108498782A (en) | A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease | |
| CN102526370A (en) | Cordyceps preparation for promoting immunity of human body and preparation method thereof | |
| CN108245538A (en) | A kind of ginkgo biloba p.e and its medical usage | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN110478450B (en) | Pharmaceutical composition for treating Alzheimer disease and application thereof | |
| CN108478701A (en) | A kind of lozenge of strengthen immunity | |
| CN115429836B (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN107536938A (en) | A kind of vital energy regualting and blood circulation-promoting preparation is preparing the application in treating or preventing renal damage medicine | |
| CN105456684A (en) | Traditional Chinese medicine composition for Qi-Yin deficiency type atrial fibrillation and preparation method thereof | |
| CN104547695B (en) | It is a kind of for treating the pharmaceutical composition and its application of trigeminal neuralgia | |
| CN104206597A (en) | Schisandra chinensis health tea capable of relieving lung and kidney yin deficiency symptoms and preparation method of schisandra chinensis heath tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |